Pricing Log in Create free account
Saturday 17 October 2026 Export ORGS’s income statement to Excel — free account

Orgenesis Inc.

ORGS Healthcare Biotechnology

Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.

0.06 0.06 Infinity
Market cap
$5.7M
P/E
0.0×
Fwd P/E
1.0×
Dividend yield
—
F-score
3/9
Altman Z
−352.42
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 5.68
Revenue 1.04
Net Income (49.01)
Free Cash Flow (17.34)
Net Debt 16.01
Current Ratio 0.03 (below 1: weak)
Debt/Equity (0.44) (negative: negative equity)
P/E ratio 0.00
Fwd P/E 1.02
P/S ratio 0.24
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth 13,164.15% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 15.7×, against a ten-year median of 7.4×; over the ten years it ranged from −5.4× in 2020 to 85.7× in 2024.
P/S against its own 10 years 1.14%
10-year low 10-year high
EV/Sales against its own 10 years 71.95%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2021 2022 2023 2024
Cash 6 6 1 1
Receivables 15 36 1 0
Inventory 0 0 0 —
Other 3 3 — —
26 46 4 1
2021 2022 2023 2024
Payables 5 4 7 13
ST’ Debt 6 5 3 8
Other 0 — — —
15 16 16 27

Compound Annual Growth %

10y 5y 3y
Sales (16.65%) (23.30%) (69.22%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 0 0 0 0 1
’23 0 0 0 0 1
’22 7 7 8 14 36
’21 9 11 9 7 36
’20 2 2 2 2 8
’19 0 1 1 1 4
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 (4) (6) (5) (2) (17)
’23 (7) (6) (1) (1) (15)
’22 (3) (6) (5) (11) (25)
’21 (5) (11) (8) (2) (27)
’20 (14) (9) (10) (45) (78)
’19 (5) (4) (2) (3) (13)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 (5) (6) (5) (2) (17)
’23 (9) (6) (1) (1) (17)
’22 (4) (10) (8) (16) (37)
’21 (5) (13) (10) (7) (35)
’20 (14) (9) (10) (45) (80)
’19 (5) (5) (6) (9) (25)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’24 (2.90) (2.30) (1.93) (4.38) (11.44)
’23 (8.83) (1.50) (1.24) (1.40) (19.10)
’22 1.62 2.21 0.55 (9.24) (5.90)
’21 (0.10) (1.12) (4.18) (2.00) (7.40)
’20 42.30 9.50 (1.10) (28.20) 2.90
’19 5.50 3.60 4.40 (4.20) (17.70)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Trend 2025e 2026e 2027e
Price, $
Price, $ Low — 28.22 27.60 38.70 23.50 27.60 25.60 11.30 3.84 0.87

Analyst estimates 2025–2027

Powerpack
High — 61.80 117.60 168.00 59.28 82.00 83.00 40.40 26.40 10.80
People
People Employees — 80 103 231 309 111 151 167 146 77
Revenue/emp, $m — 0.00 0.00 0.00 0.01 0.07 0.24 0.22 0.00 0.01
Income, $m
Income, $m Revenue — 6 10 21 4 8 36 36 1 1
Gross margin, % — (45.02) 15.27 41.26 (259.43) (997.57) (3.22) 85.75 (1,080.19) (86.28)
EBT — (13) (14) (21) (23) (97) (18) (12) (64) (49)
EBT margin, % — (197.91) (135.56) (101.22) (585.23) (1,264.19) (50.56) (33.20) (12,159.43) (4,726.18)
Net income — (11) (12) (22) (26) 1 (18) (12) (65) (49)
Depreciation — 3 3 3 4 1 2 2 2 2
Per share, $
Per share, $ Revenue — 0.75 1.04 15.33 2.45 3.59 14.63 14.35 0.18 0.25
Earnings — (1.30) (1.31) (14.30) (17.70) 2.90 (7.40) (5.90) (19.10) (11.44)
Cash flow — (0.44) (0.40) (12.53) (8.31) (36.61) (11.07) (9.93) (5.11) (4.06)
Capex — 0.00 0.00 (4.55) (7.57) (0.71) (3.24) (4.85) (0.72) (0.06)
Free cash flow — (0.44) (0.40) (17.09) (15.89) (37.32) (14.31) (14.78) (5.84) (4.12)
Book value — 1.47 1.46 20.00 3.82 24.73 15.91 11.58 (7.23) (8.91)
Shares, m — 9 10 1 2 2 2 3 3 4
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 5.01 2.00 0.00 0.00 0.00 0.00
P/S — 5.95 6.31 3.05 19.01 12.54 1.97 1.37 26.93 7.69
P/B — 4.10 3.83 2.34 12.20 1.82 1.81 1.69 0.00 0.00
EV/Sales — 7.46 6.81 2.54 22.19 8.07 2.10 1.69 66.20 23.15
EV/FCF — 8.68 26.10 (2.28) (3.42) (0.78) (2.15) (1.64) (2.07) (1.38)
Cash, $m
Cash, $m Operating cash flow — (4) (4) (17) (13) (78) (27) (25) (15) (17)
Capex — (1) (1) (6) (12) (2) (8) (12) (2) 0
Free cash flow — (4) (4) (23) (25) (80) (35) (37) (17) (17)
Balance, $m
Balance, $m Working capital — (10) (10) 11 36 34 10 30 (12) (26)
Total debt — 10 8 5 13 11 11 18 22 17
Net debt — 9 4 (10) 12 (34) 5 12 21 16
Shareholders’ equity — 12 14 27 6 53 39 29 (21) (38)
Returns, %
Returns, % ROA — (33.19) (31.02) (29.60) (29.00) 1.30 (26.25) (19.75) (104.97) (605.73)
ROIC — 0.00 0.00 (64.80) (74.42) (322.83) (24.17) (15.55) 0.00 0.00
ROE — (88.93) (87.57) (79.78) (146.95) 3.78 (39.52) (43.98) (1,368.97) 164.62
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2024

Charts ten years each

Orgenesis Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TRAW Traws Pharma, Inc. $6.2M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −25.51% (below 0%: shrinking) 0.00% 0.00% Compare
ALZN Alzamend Neuro, Inc. $6.2M — (loss-making) — — n/m +51.82% (above 0%: growing) 0.00% 0.00% Compare
NRSN NeuroSense Therapeutics Ltd. $6.0M — (loss-making) — — n/m −23,458.82% (below 0%: shrinking) — 0.00% Compare
IMNN Imunon, Inc. $6.0M — (loss-making) — (loss-making) 0.00% n/m −4.24% (below 0%: shrinking) 0.00% 0.00% Compare
ORGS Orgenesis Inc. $5.7M — (loss-making) 1.0× +82.42% (above 0%: growing) n/m −317.93% (below 0%: shrinking) 2,780.73% (6,044.52%)
CANF Can-Fite Biopharma Ltd $5.6M — (loss-making) — (loss-making) −1.18% (below 0%: shrinking) n/m +12.63% (above 0%: growing) 0.00% 0.00% Compare
BGMS Bio Green Med Solution, Inc. $5.5M — (loss-making) — (loss-making) +3,260.00% (above 0%: growing) n/m +66.67% (above 0%: growing) 23.51% (124.40%) Compare
CELZ Creative Medical Technology Holdings, Inc. $5.4M — (loss-making) — (loss-making) 0.00% n/m −27.05% (below 0%: shrinking) 66.67% 0.00% Compare
CDIO Cardio Diagnostics Holdings, Inc. $5.2M — (loss-making) — (loss-making) −28.00% (below 0%: shrinking) n/m +15.58% (above 0%: growing) 100.00% (27,742.59%) Compare
Median of peers $5.8M — — −0.59% — +4.20% 0.00% 0.00%

All 614 Biotechnology stocks →

Orgenesis Inc. (ORGS) key facts

  • Strength: Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023.
  • Orgenesis Inc. (ORGS) is a Biotechnology company in the Healthcare sector.
  • As of October 15, 2026, ORGS traded at $0.06, a market capitalization of $5.7 million.
  • Return on equity was 164.6% and debt-to-equity -0.44.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −352.42 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.

Orgenesis Inc. (ORGS) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ORGS · Data as of Dec 31, 2024 · For information only; not investment advice. · © 2026 stockrow.com